Canagliflozin not associated with increased risk for fracture
(American College of Physicians) Compared with a glucagon-line peptide-1 (GLP-1) agonist, canagliflozin was not associated with an increased risk for fracture in patients with type 2 diabetes at relatively low risk for fracture. Findings from a multidatabase cohort study are published in Annals of Internal Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Internal Medicine | International Medicine & Public Health | Invokana | Study